B. Metzler seel. Sohn & Co. AG Takes $3.60 Million Position in Repligen Corporation $RGEN

Key Points

• B. Metzler seel. Sohn & Co. AG acquired 26,361 Repligen shares in the second quarter, valued at approximately $3.60 million. Institutional investors collectively own 97.64% of the company.
• Repligen reported quarterly EPS of $0.54, exceeding the $0.45 analyst consensus, while revenue reached $204.13 million, up 11.9% year over year and above estimates.
• Analyst sentiment remains positive, with an average rating of “Buy” and an average price target of $166.43, although the stock’s valuation is elevated at a P/E ratio of 248.12.

B. Metzler seel. Sohn & Co. AG acquired a new position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 26,361 shares of the biotechnology company's stock, valued at approximately $3,597,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Measured Wealth Private Client Group LLC acquired a new position in Repligen during the third quarter worth about $29,000. Bayforest Capital Ltd acquired a new position in shares of Repligen in the 4th quarter valued at approximately $32,000. Rachor Investment Advisory Services LLC acquired a new position in Repligen in the fourth quarter worth $33,000. Los Angeles Capital Management LLC acquired a new stake in shares of Repligen during the 4th quarter worth approximately $36,000. Finally, Farther Finance Advisors LLC increased its stake in shares of Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 128 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Trading Up 0.5%

RGEN opened at $181.13 on Friday. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $10.22 billion, a PE ratio of 248.12, a PEG ratio of 3.29 and a beta of 1.03. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $188.73. The firm has a 50-day moving average price of $147.16 and a two-hundred day moving average price of $131.88.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.45 by $0.09. The company had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. Repligen's quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, equities analysts anticipate that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on RGEN. Weiss Ratings raised shares of Repligen from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, August 13th. Zacks Research raised Repligen from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 30th. HSBC reduced their price objective on shares of Repligen from $170.00 to $150.00 and set a "buy" rating for the company in a research note on Wednesday, June 3rd. Evercore reaffirmed an "outperform" rating and set a $160.00 target price on shares of Repligen in a research report on Monday, July 6th. Finally, Wolfe Research assumed coverage on shares of Repligen in a report on Tuesday, June 2nd. They set an "outperform" rating and a $145.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, Repligen has an average rating of "Buy" and an average price target of $166.43.

Insider Transactions at Repligen

In other news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the sale, the chief financial officer directly owned 19,359 shares of the company's stock, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.60% of the company's stock.

Repligen Company Profile

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source